Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Imatinib Mesylate

FDA-approved product (capsule, oral), marketed as Gleevec, Imatinib Mesylate, Imkeldi.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Imatinib Mesylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute lymphoblastic leukemia
  • B-cell acute lymphoblastic leukemia
  • Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Childhood acute lymphoblastic leukemia
  • Chronic myelogenous leukemia
  • Dermatofibrosarcoma protuberans
  • Gastrointestinal stromal tumor
  • Hypereosinophilic syndrome
  • Lymphoblastic lymphoma
  • Myelodysplastic/myeloproliferative disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Bcr-abl tyrosine kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA64.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli48.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Imatinib Mesylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Imatinib Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • COMPERA / COMPERA-KIDS

    NCT01347216 · start 2007-07-01

    Registered record
    Registry ID
    NCT01347216
    Conditions
    Pulmonary Arterial Hypertension (PAH); Pulmonary Hypertension (PH)
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2007-07-01
    Completion
    2026-12-31
    Enrolment
    14,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Arterial Hypertension (PAH); Pulmonary Hypertension (PH)
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • Effects of Imatinib Mesylate in Polycythemia Vera

    NCT00430066 · start 2007-02

    Registered record
    Registry ID
    NCT00430066
    Conditions
    Polycythemia Vera
    Interventions
    Imatinib Mesylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-02
    Completion
    2012-09
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycythemia Vera
    InterventionImatinib Mesylate
    PhasePhase 2
    Registry statusCompleted

  • Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)

    NCT00415857 · start 2006-12

    Registered record
    Registry ID
    NCT00415857
    Conditions
    Leukemia
    Interventions
    Peptide Vaccine (PR1 Peptide); Peginterferon alfa-2b; Imatinib; GM-CSF
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2006-12
    Completion
    2013-09
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia
    InterventionPeptide Vaccine (PR1 Peptide); Peginterferon alfa-2b; Imatinib; GM-CSF
    PhasePhase 2
    Registry statusTerminated

  • TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients

    NCT00415909 · start 2006-12

    Registered record
    Registry ID
    NCT00415909
    Conditions
    Chronic Myelogenous Leukemia
    Interventions
    Imatinib Mesylate (IM); TALL-104 cells
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2006-12
    Completion
    2013-05
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myelogenous Leukemia
    InterventionImatinib Mesylate (IM); TALL-104 cells
    PhasePhase 2
    Registry statusTerminated

  • Ph II Study of Perifosine Plus Gleevec for Patients With GIST

    NCT00455559 · start 2006-08

    Registered record
    Registry ID
    NCT00455559
    Conditions
    Gastrointestinal Stromal Tumors
    Interventions
    Perifosine; Imatinib Mesylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-08
    Completion
    2011-10
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumors
    InterventionPerifosine; Imatinib Mesylate
    PhasePhase 2
    Registry statusCompleted

  • Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer

    NCT00323791 · start 2006-04

    Registered record
    Registry ID
    NCT00323791
    Conditions
    Kidney Cancer
    Interventions
    gemcitabine hydrochloride; imatinib mesylate; gene expression analysis; protein expression analysis; immunohistochemistry staining method; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2006-04
    Completion
    2007-08
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Cancer
    Interventiongemcitabine hydrochloride; imatinib mesylate; gene expression analysis; protein expression analysis +2 more
    PhasePhase 2
    Registry statusTerminated

  • Imatinib Mesylate and Combination Chemotherapy With or Without a Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

    NCT00618501 · start 2005-10

    Registered record
    Registry ID
    NCT00618501
    Conditions
    Leukemia
    Interventions
    cytarabine; daunorubicin hydrochloride; etoposide; imatinib mesylate; leucovorin calcium; methotrexate; prednisolone; therapeutic hydrocortisone; vincristine sulfate; allogeneic hematopoietic stem cell transplantation
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-10
    Completion
    2009-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia
    Interventioncytarabine; daunorubicin hydrochloride; etoposide; imatinib mesylate +6 more
    PhasePhase 2
    Registry statusCompleted

  • Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)

    NCT00290485 · start 2005-08

    Registered record
    Registry ID
    NCT00290485
    Conditions
    Gastrointestinal Stromal Tumors
    Interventions
    Imatinib mesylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2005-08
    Completion
    Not recorded
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumors
    InterventionImatinib mesylate
    PhasePhase 2
    Registry statusUnknown

  • Role of Gene Variation in Effectiveness of Gleevec Treatment

    NCT00342056 · start 2005-01

    Registered record
    Registry ID
    NCT00342056
    Conditions
    Cancer; Breast Cancer
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2005-01
    Completion
    2008-10
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer; Breast Cancer
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia

    NCT00458848 · start 2004-10

    Registered record
    Registry ID
    NCT00458848
    Conditions
    Leukemia
    Interventions
    asparaginase; daunorubicin hydrochloride; etoposide; idarubicin; imatinib mesylate; mercaptopurine; methotrexate; methylprednisolone; mitoxantrone hydrochloride; prednisone; vincristine sulfate; allogeneic hematopoietic stem cell transplantation; autologous hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-10
    Completion
    2014-03
    Enrolment
    470

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia
    Interventionasparaginase; daunorubicin hydrochloride; etoposide; idarubicin +11 more
    PhasePhase 2
    Registry statusCompleted

  • Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes

    NCT00171912 · start 2004-09

    Registered record
    Registry ID
    NCT00171912
    Conditions
    Hypereosinophilic Syndrome; Systemic Mastocytosis; Chronic Myelomonocytic Leukemia; Dermatofibrosarcoma
    Interventions
    imatinib mesylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-09
    Completion
    2012-01
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypereosinophilic Syndrome; Systemic Mastocytosis; Chronic Myelomonocytic Leukemia; Dermatofibrosarcoma
    Interventionimatinib mesylate
    PhasePhase 2
    Registry statusCompleted

  • Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck

    NCT00180921 · start 2004-07

    Registered record
    Registry ID
    NCT00180921
    Conditions
    Cancer of the Head and Neck; Carcinoma, Adenoid Cystic
    Interventions
    Imatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2004-07
    Completion
    Not recorded
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer of the Head and Neck; Carcinoma, Adenoid Cystic
    InterventionImatinib
    PhasePhase 2
    Registry statusUnknown

  • Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients

    NCT00499889 · start 2003-02

    Registered record
    Registry ID
    NCT00499889
    Conditions
    Leukemia
    Interventions
    Imatinib Mesylate; Fludarabine (Fludara); Busulfan; Antithymocyte Globulin (ATG); Tacrolimus; Methotrexate; Donor lymphocyte infusion (DLI); Stem Cell Transplant
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2003-02
    Completion
    2009-11
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia
    InterventionImatinib Mesylate; Fludarabine (Fludara); Busulfan; Antithymocyte Globulin (ATG) +4 more
    PhasePhase 2
    Registry statusTerminated

  • Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)

    NCT00130195 · start 2002-09

    Registered record
    Registry ID
    NCT00130195
    Conditions
    Acute Lymphoblastic Leukemia
    Interventions
    imatinib; cyclophosphamide; daunorubicin; vincristine; prednisolone; methotrexate; cytarabine; dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-09
    Completion
    2008-05
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Lymphoblastic Leukemia
    Interventionimatinib; cyclophosphamide; daunorubicin; vincristine +4 more
    PhasePhase 2
    Registry statusCompleted

  • Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

    NCT00042016 · start 2002-07

    Registered record
    Registry ID
    NCT00042016
    Conditions
    Chronic Myelogenous Leukemia
    Interventions
    decitabine (5-aza-2'deoxycytidine)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-07
    Completion
    Not recorded
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myelogenous Leukemia
    Interventiondecitabine (5-aza-2'deoxycytidine)
    PhasePhase 2
    Registry statusCompleted